Free Trial
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel Free ARWR Stock Alerts

Arrowhead Pharmaceuticals (ARWR) Financials

Arrowhead Pharmaceuticals logo
$73.95 -2.72 (-3.55%)
Closing price 04:00 PM Eastern
Extended Trading
$73.97 +0.02 (+0.03%)
As of 06:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Arrowhead Pharmaceuticals

Annual Income Statements for Arrowhead Pharmaceuticals

This table shows Arrowhead Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 9/30/2015 9/30/2016 9/30/2017 9/30/2018 9/30/2019 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024 9/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 -92 -82 -34 -54 68 -85 -141 -176 -205 -599 -1.63
Consolidated Net Income / (Loss)		 -92 -82 -34 -54 68 -85 -141 -176 -209 -610 30
Net Income / (Loss) Continuing Operations		 -92 -82 -34 -54 68 -85 -141 -176 -209 -610 30
Total Pre-Tax Income 		-92 -82 -34 -54 68 -85 -141 -173 -206 -612 52
Total Operating Income		 -96 -82 -37 -56 61 -93 -149 -179 -205 -601 98
Total Gross Profit		 0.38 0.16 31 16 169 88 138 243 241 3.55 829
Total Revenue		 0.38 0.16 31 16 169 88 138 243 241 3.55 829
Operating Revenue		 0.38 0.16 31 16 169 88 138 243 241 3.55 829
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 96 82 68 72 108 181 287 422 446 605 731
Selling, General & Admin Expense		 24 24 17 19 27 52 81 124 93 99 124
Research & Development Expense		 57 62 51 53 81 129 206 297 353 506 607
Total Other Income / (Expense), net		 4.04 0.02 2.62 1.49 6.96 8.61 8.19 5.80 -1.49 -11 -47
Interest Expense		 - - - - - - 0.00 0.00 18 32 89
Interest & Investment Income		 0.73 0.27 0.42 1.05 6.96 9.19 6.12 5.03 15 23 37
Other Income / (Expense), net		 3.31 -0.24 2.20 0.44 0.00 -0.58 2.07 0.77 1.54 -1.75 5.26
Income Tax Expense		 0.00 0.00 0.00 0.00 0.17 0.00 0.00 3.79 2.78 -2.77 21
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - - - - 0.00 0.00 -0.43 -4.00 -10 32
Basic Earnings per Share		 ($1.60) ($1.34) ($0.47) ($0.65) $0.72 ($0.84) ($1.36) ($1.67) ($1.92) ($5.00) ($0.01)
Weighted Average Basic Shares Outstanding		 57.36M 61.05M 73.90M 83.64M 93.86M 100.72M 103.75M 105.43M 106.75M 119.78M 133.76M
Diluted Earnings per Share		 ($1.60) ($1.34) ($0.47) ($0.65) $0.69 ($0.84) ($1.36) ($1.67) ($1.92) ($5.00) ($0.01)
Weighted Average Diluted Shares Outstanding		 57.36M 61.05M 73.90M 83.64M 98.61M 100.72M 103.75M 105.43M 106.75M 119.78M 133.76M
Weighted Average Basic & Diluted Shares Outstanding		 57.36M 61.05M 73.90M 83.64M 95.71M 102.76M 104.53M 106.01M 107.43M 124.43M 135.81M

Quarterly Income Statements for Arrowhead Pharmaceuticals

This table shows Arrowhead Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -110 -133 -125 -171 -171 -173 370 -175 -24 31 -133
Consolidated Net Income / (Loss)		 -111 -135 -127 -174 -173 -175 368 -179 16 28 -138
Net Income / (Loss) Continuing Operations		 -111 -135 -127 -174 -173 -175 368 -179 16 28 -138
Total Pre-Tax Income 		-109 -139 -127 -174 -173 -175 370 -179 36 28 -138
Total Operating Income		 -108 -137 -126 -176 -162 -161 381 -166 44 41 -141
Total Gross Profit		 16 3.55 0.00 0.00 - 2.50 543 28 256 264 74
Total Revenue		 16 3.55 0.00 0.00 - 2.50 543 28 256 264 74
Operating Revenue		 16 3.55 0.00 0.00 - 2.50 543 28 256 264 74
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 124 140 126 176 162 164 162 193 212 223 215
Selling, General & Admin Expense		 25 24 25 24 26 27 28 31 38 46 42
Research & Development Expense		 100 116 101 152 136 137 133 162 175 177 173
Total Other Income / (Expense), net		 -0.66 -2.14 -0.81 2.16 -11 -14 -12 -14 -7.99 -13 3.70
Interest Expense		 5.26 5.37 7.24 5.09 15 22 22 24 22 23 24
Interest & Investment Income		 3.89 2.80 6.25 6.50 7.17 7.60 9.62 11 9.05 9.69 10
Other Income / (Expense), net		 0.72 0.42 0.19 0.76 -3.12 0.34 0.44 -0.18 4.66 0.28 17
Income Tax Expense		 2.04 -3.31 0.00 0.00 0.55 0.10 1.75 -0.44 20 0.03 0.01
Net Income / (Loss) Attributable to Noncontrolling Interest		 -1.34 -2.51 -1.70 -3.18 -2.81 -2.13 -2.58 -3.41 40 -2.57 -4.84
Basic Earnings per Share		 ($1.03) ($1.24) ($1.02) ($1.38) ($1.36) ($1.39) $2.78 ($1.26) ($0.14) $0.22 ($0.93)
Weighted Average Basic Shares Outstanding		 106.75M 107.42M 123.29M 124.20M 119.78M 124.85M 133.36M 139.04M 133.76M 137.04M 142.42M
Diluted Earnings per Share		 ($1.02) ($1.24) ($1.02) ($1.38) ($1.36) ($1.39) $2.75 ($1.26) ($0.11) $0.22 ($0.93)
Weighted Average Diluted Shares Outstanding		 106.75M 107.42M 123.29M 124.20M 119.78M 124.85M 134.48M 139.04M 133.76M 140.71M 142.42M
Weighted Average Basic & Diluted Shares Outstanding		 107.43M 123.90M 124.20M 124.32M 124.43M 126.10M 138.10M 138.26M 135.81M 140.03M 140.86M

Annual Cash Flow Statements for Arrowhead Pharmaceuticals

This table details how cash moves in and out of Arrowhead Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 9/30/2015 9/30/2016 9/30/2017 9/30/2018 9/30/2019 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024 9/30/2025
Net Change in Cash & Equivalents		 -51 4.15 -61 5.29 192 -79 41 -76 3.01 -12 124
Net Cash From Operating Activities		 -66 -64 -24 -47 173 -96 171 -136 -154 -463 180
Net Cash From Continuing Operating Activities		 -66 -64 -24 -47 173 -96 171 -136 -154 -463 180
Net Income / (Loss) Continuing Operations		 -92 -82 -34 -54 68 -85 -141 -176 -209 -610 30
Consolidated Net Income / (Loss)		 -92 -82 -34 -54 68 -85 -141 -176 -209 -610 30
Depreciation Expense		 2.34 3.26 4.69 4.70 4.44 5.94 8.27 10 12 19 24
Amortization Expense		 1.11 0.23 -0.04 0.38 1.07 0.53 0.27 2.91 -2.02 -3.24 -5.79
Non-Cash Adjustments To Reconcile Net Income		 20 14 7.89 8.45 12 44 78 139 143 109 145
Changes in Operating Assets and Liabilities, net		 2.43 0.16 -2.10 -6.31 87 -62 225 -112 -98 23 -14
Net Cash From Investing Activities		 14 13 -49 -7.43 -48 -241 -142 -5.42 -96 -420 -129
Net Cash From Continuing Investing Activities		 14 13 -49 -7.43 -48 -241 -142 -5.42 -96 -420 -129
Purchase of Property, Plant & Equipment		 -12 -3.86 -7.92 -1.42 -12 -12 -24 -53 -177 -141 -23
Purchase of Investments		 0.00 0.00 -45 -52 -90 -279 -241 -223 -246 -721 -796
Sale and/or Maturity of Investments		 26 17 4.25 46 55 50 123 271 327 442 690
Net Cash From Financing Activities		 0.29 55 12 60 66 258 11 65 253 871 74
Net Cash From Continuing Financing Activities		 0.29 55 12 60 66 258 11 65 253 871 74
Repayment of Debt		 -0.21 -0.22 -0.20 -0.21 -2.42 - - 0.00 0.00 -3.13 -207
Issuance of Debt		 - - - - - - - 0.00 0.00 392 10
Issuance of Common Equity		 0.00 52 12 57 61 250 - 0.00 0.00 429 266
Other Financing Activities, net		 0.50 3.12 -0.17 3.58 8.28 7.47 11 65 253 52 3.98
Cash Interest Paid		 0.01 0.01 0.19 0.17 0.03 0.00 0.00 - 0.00 0.00 0.02
Cash Income Taxes Paid		 0.00 0.00 0.00 -0.00 -0.30 0.10 -0.00 -0.00 0.00 -3.74 0.81

Quarterly Cash Flow Statements for Arrowhead Pharmaceuticals

This table details how cash moves in and out of Arrowhead Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 5.40 -53 69 -58 29 -49 132 -56 97 -25 -14
Net Cash From Operating Activities		 -26 -118 -92 -115 -137 -146 460 -155 20 13 84
Net Cash From Continuing Operating Activities		 -26 -118 -92 -115 -137 -146 460 -155 20 13 84
Net Income / (Loss) Continuing Operations		 -111 -135 -127 -174 -173 -175 368 -179 16 28 -138
Consolidated Net Income / (Loss)		 -111 -135 -127 -174 -173 -175 368 -179 16 28 -138
Depreciation Expense		 3.86 4.26 4.53 4.78 5.03 5.24 6.08 6.22 6.39 6.39 6.37
Amortization Expense		 -0.99 -0.84 1.73 6.99 -11 - 2.92 -1.76 -1.24 -1.22 -0.64
Non-Cash Adjustments To Reconcile Net Income		 68 29 26 22 33 31 37 36 36 41 26
Changes in Operating Assets and Liabilities, net		 14 -15 2.75 25 9.59 -7.44 47 -17 -37 -61 189
Net Cash From Investing Activities		 31 65 -269 6.95 -223 77 -420 141 73 -24 -894
Net Cash From Continuing Investing Activities		 31 65 -269 6.95 -223 77 -420 141 73 -24 -894
Purchase of Property, Plant & Equipment		 -64 -69 -34 -14 -24 -7.52 -5.30 -2.36 -7.49 -2.15 -2.57
Purchase of Investments		 -12 0.00 -310 -119 -292 -34 -644 -97 -22 -137 -925
Sale and/or Maturity of Investments		 107 133 75 140 94 118 229 240 102 115 33
Net Cash From Financing Activities		 0.82 0.27 431 50 389 21 92 -43 3.67 -15 796
Net Cash From Continuing Financing Activities		 0.82 0.27 431 50 389 21 92 -43 3.67 -15 796
Repayment of Debt		 - 0.00 - - - -5.00 -152 -50 - -67 -37
Issuance of Common Equity		 - 0.00 - - - 25 241 - - 47 231
Other Financing Activities, net		 0.82 0.27 1.51 50 0.22 0.63 2.62 0.22 0.51 5.10 -43
Cash Income Taxes Paid		 - -1.00 -2.02 -0.05 -0.68 0.01 0.09 - 0.73 9.91 12

Annual Balance Sheets for Arrowhead Pharmaceuticals

This table presents Arrowhead Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 9/30/2015 9/30/2016 9/30/2017 9/30/2018 9/30/2019 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024 9/30/2025
Total Assets		 132 128 104 112 350 523 710 692 766 1,140 1,385
Total Current Assets		 103 91 68 79 265 322 385 405 416 695 951
Cash & Equivalents		 81 85 25 30 222 144 184 108 111 103 227
Short-Term Investments		 18 0.00 41 46 37 172 183 268 293 578 693
Accounts Receivable		 0.00 0.08 0.07 0.33 0.66 0.85 10 1.41 - 0.00 6.82
Prepaid Expenses		 3.29 1.29 0.87 1.27 3.32 4.25 4.36 7.29 8.81 9.54 11
Other Current Assets		 0.82 3.77 1.36 0.64 2.56 1.78 2.19 20 4.03 4.97 14
Plant, Property, & Equipment, net		 4.53 15 16 14 23 31 49 110 290 386 383
Total Noncurrent Assets		 25 22 21 19 61 169 277 176 59 58 52
Intangible Assets		 25 22 20 19 17 15 14 12 10 8.56 6.86
Other Noncurrent Operating Assets		 0.05 0.12 0.14 0.14 0.14 16 18 59 49 50 45
Total Liabilities & Shareholders' Equity		 132 128 104 112 350 523 710 692 766 1,140 1,385
Total Liabilities		 23 33 23 16 106 61 301 274 478 949 882
Total Current Liabilities		 16 26 19 12 97 41 147 139 105 103 195
Short-Term Debt		 0.22 0.19 0.21 0.22 - - - - - 0.00 40
Accounts Payable		 5.03 12 4.08 2.81 7.65 6.83 9.46 2.87 36 11 18
Accrued Expenses		 5.38 4.59 4.56 5.04 6.50 5.39 14 47 40 63 90
Current Deferred Revenue		 0.10 3.01 5.71 0.31 78 19 111 74 0.87 0.00 2.40
Current Employee Benefit Liabilities		 3.82 3.97 3.40 3.94 4.96 8.06 9.77 12 18 22 27
Other Current Liabilities		 1.35 1.65 0.74 0.05 0.02 1.11 2.25 2.78 11 6.77 18
Total Noncurrent Liabilities		 6.75 7.51 4.45 4.00 8.74 20 155 135 373 846 686
Long-Term Debt		 0.00 2.53 2.33 2.10 - - - - 0.00 393 215
Noncurrent Deferred Revenue		 0.14 4.77 1.93 1.70 8.74 0.00 131 56 - - 0.00
Other Noncurrent Operating Liabilities		 6.06 0.20 0.20 0.20 0.00 20 23 79 268 452 472
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 110 95 81 95 244 462 409 418 287 191 503
Total Preferred & Common Equity		 110 96 81 96 245 462 409 399 271 185 466
Total Common Equity		 110 96 81 96 245 462 409 399 271 185 466
Common Stock		 427 494 514 583 664 966 1,054 1,219 1,301 1,806 2,140
Retained Earnings		 -317 -398 -433 -487 -419 -504 -645 -821 -1,026 -1,626 -1,627
Treasury Stock		 - - - - - - - - - 0.00 -53
Accumulated Other Comprehensive Income / (Loss)		 -0.14 0.01 0.03 -0.02 -0.39 0.02 -0.07 -0.14 -3.22 4.75 6.44
Noncontrolling Interest		 -0.56 -0.56 -0.56 -0.56 -0.56 - 0.00 20 16 5.62 37

Quarterly Balance Sheets for Arrowhead Pharmaceuticals

This table presents Arrowhead Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 12/31/2022 3/31/2023 6/30/2023 12/31/2023 3/31/2024 6/30/2024 12/31/2024 3/31/2025 6/30/2025 12/31/2025 3/31/2026
Total Assets		 891 891 796 626 955 884 1,014 1,573 1,381 1,604 2,268
Total Current Assets		 575 575 470 238 542 450 571 1,135 947 1,174 1,840
Cash & Equivalents		 202 135 105 58 128 69 54 186 130 202 189
Short-Term Investments		 300 346 346 162 395 367 499 912 771 715 1,596
Accounts Receivable		 40 69 1.25 - - - 2.50 2.37 9.70 219 16
Prepaid Expenses		 8.41 9.94 10 11 11 9.21 9.37 24 24 16 22
Other Current Assets		 25 14 7.16 7.10 7.51 4.18 5.74 12 13 23 18
Plant, Property, & Equipment, net		 147 185 231 333 359 376 387 385 381 379 375
Total Noncurrent Assets		 169 131 94 55 54 58 56 53 53 51 54
Intangible Assets		 12 11 11 9.84 9.41 8.99 8.14 7.71 7.29 6.44 6.01
Other Noncurrent Operating Assets		 42 41 41 45 45 49 48 46 45 45 48
Total Liabilities & Shareholders' Equity		 891 891 796 626 955 884 1,014 1,573 1,381 1,604 2,268
Total Liabilities		 495 426 414 453 460 545 958 889 861 1,041 1,669
Total Current Liabilities		 122 87 70 64 65 97 94 221 195 347 295
Short-Term Debt		 - - - - - - 1.63 65 40 40 40
Accounts Payable		 0.80 9.56 7.87 4.46 8.52 27 14 9.98 33 33 31
Accrued Expenses		 48 40 38 47 37 48 59 78 65 130 77
Current Deferred Revenue		 66 30 17 0.00 0.00 0.00 - 43 23 112 109
Current Employee Benefit Liabilities		 4.09 5.49 4.43 8.78 14 16 11 17 19 14 20
Other Current Liabilities		 2.66 2.71 2.82 3.88 5.86 6.47 7.00 7.23 14 18 19
Total Noncurrent Liabilities		 373 339 344 389 395 448 864 669 666 694 1,374
Long-Term Debt		 - - - - - - 408 209 200 163 842
Capital Lease Obligations		 79 80 80 115 114 112 109 108 106 102 100
Noncurrent Deferred Revenue		 41 1.08 0.00 - - - - - - 54 49
Other Noncurrent Operating Liabilities		 253 258 264 274 281 336 347 352 360 375 384
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 396 465 382 174 495 339 56 684 520 563 599
Total Preferred & Common Equity		 377 447 365 160 484 331 53 683 522 568 614
Total Common Equity		 377 447 365 160 484 331 53 683 522 568 614
Common Stock		 1,239 1,261 1,282 1,321 1,769 1,787 1,847 2,107 2,120 2,211 2,396
Retained Earnings		 -862 -813 -916 -1,159 -1,284 -1,455 -1,799 -1,428 -1,603 -1,596 -1,729
Treasury Stock		 - - - - - - - - - -53 -53
Accumulated Other Comprehensive Income / (Loss)		 -0.26 -0.33 -0.41 -1.26 -1.10 -0.99 4.14 4.39 5.36 6.70 0.74
Noncontrolling Interest		 19 18 17 13 12 8.43 3.49 0.90 -2.51 -5.73 -15

Annual Metrics And Ratios for Arrowhead Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Arrowhead Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 9/30/2015 9/30/2016 9/30/2017 9/30/2018 9/30/2019 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024 9/30/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 118.29% -58.55% 19,736.49% -48.60% 945.67% -47.87% 57.16% 75.89% -1.03% -98.52% 23,258.15%
EBITDA Growth		 -56.29% 12.02% 61.59% -67.23% 232.30% -230.85% -58.62% -18.77% -17.38% -204.41% 120.72%
EBIT Growth		 -56.46% 11.53% 57.56% -59.51% 210.26% -253.20% -56.78% -20.94% -14.47% -196.28% 117.19%
NOPAT Growth		 -80.14% 14.83% 54.74% -51.20% 255.88% -206.84% -59.98% -19.77% -14.84% -193.21% 113.66%
Net Income Growth		 -56.56% 11.11% 57.93% -58.38% 224.84% -224.39% -66.58% -25.31% -18.57% -191.34% 104.94%
EPS Growth		 -28.00% 16.25% 64.93% -38.30% 206.15% -221.74% -61.90% -22.79% -14.97% -160.42% 99.80%
Operating Cash Flow Growth		 -85.53% 1.95% 62.84% -97.27% 466.42% -155.37% 278.82% -179.46% -13.05% -200.77% 138.79%
Free Cash Flow Firm Growth		 -208.60% 34.89% 46.01% -35.43% 432.37% -194.28% 182.07% -343.58% 26.36% -128.52% 136.27%
Invested Capital Growth		 213.48% 6.54% 43.66% 18.21% -379.77% 114.95% -2,424.83% 68.75% 81.45% 220.72% -66.54%
Revenue Q/Q Growth		 0.00% -7.32% 38.21% 18.68% 23.43% -28.84% 28.48% -2.68% -6.04% -81.93% 44.76%
EBITDA Q/Q Growth		 -2.15% 3.03% 28.08% -1.01% 46.75% -221.92% -10.22% -12.52% -14.58% -12.80% 217.53%
EBIT Q/Q Growth		 -2.49% 3.08% 24.67% -0.51% 51.52% -180.66% -10.38% -12.13% -13.29% -10.59% 193.78%
NOPAT Q/Q Growth		 -3.09% 4.04% 23.78% -1.67% 51.15% -178.91% -10.99% -11.88% -13.57% -9.85% 176.04%
Net Income Q/Q Growth		 -2.58% 3.00% 25.05% -0.05% 49.37% -246.32% -11.87% -14.66% -13.61% -11.39% 118.90%
EPS Q/Q Growth		 1.84% 4.29% 29.85% 5.80% 46.81% -236.00% -10.57% -12.84% -12.94% -7.30% 99.21%
Operating Cash Flow Q/Q Growth		 -1.70% 2.77% 3.92% 12.14% 10.53% -35.44% -6.94% -48.90% 21.76% -31.66% 721.94%
Free Cash Flow Firm Q/Q Growth		 -2.72% -0.33% 4.75% 10.76% 3.50% -9.63% -23.12% -25.72% 3.19% -3.95% 556.48%
Invested Capital Q/Q Growth		 -41.69% -31.58% 4.74% -19.06% 15.68% -68.60% 1.56% 40.94% 63.59% -0.22% -366.27%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -23,356.26% -49,575.55% -95.98% -312.31% 39.51% -99.19% -100.11% -67.59% -80.17% -16,543.99% 14.68%
Operating Margin		 -25,124.08% -51,627.09% -117.79% -346.52% 36.25% -105.87% -107.77% -73.39% -85.16% -16,927.06% 11.86%
EBIT Margin		 -24,258.54% -51,780.99% -110.78% -343.80% 36.25% -106.53% -106.28% -73.08% -84.52% -16,976.29% 12.49%
Profit (Net Income) Margin		 -24,068.29% -51,614.64% -109.46% -337.32% 40.27% -96.09% -101.85% -72.56% -86.93% -17,169.61% 3.63%
Tax Burden Percent		 100.00% 100.00% 100.01% 100.00% 99.74% 100.00% 100.00% 102.19% 101.35% 99.55% 58.44%
Interest Burden Percent		 99.21% 99.68% 98.81% 98.11% 111.37% 90.20% 95.84% 97.17% 101.49% 101.60% 49.74%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.26% 0.00% 0.00% 0.00% 0.00% 0.00% 41.56%
Return on Invested Capital (ROIC)		 -9,727.21% -476.61% -171.63% -201.70% 0.00% 0.00% 0.00% 0.00% 0.00% -34,263.52% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -9,709.16% -449.48% -159.98% -179.42% 0.00% 0.00% 0.00% 0.00% 0.00% -34,184.09% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 9,660.50% 396.74% 132.54% 139.86% 0.00% 0.00% 0.00% 0.00% 0.00% 34,008.54% 0.00%
Return on Equity (ROE)		 -66.72% -79.87% -39.09% -61.84% 40.07% -23.96% -32.36% -42.67% -59.33% -254.98% 8.67%
Cash Return on Invested Capital (CROIC)		 -765.99% -482.94% -207.46% -218.39% 0.00% -1,509.88% 0.00% 0.00% 0.00% -3,122.72% 0.00%
Operating Return on Assets (OROA)		 -58.82% -62.96% -29.97% -51.47% 26.52% -21.49% -23.85% -25.35% -27.92% -63.28% 8.21%
Return on Assets (ROA)		 -58.36% -62.76% -29.61% -50.50% 29.46% -19.39% -22.85% -25.18% -28.72% -64.00% 2.39%
Return on Common Equity (ROCE)		 -66.99% -80.30% -39.34% -62.23% 40.20% -23.98% -32.36% -41.65% -56.33% -243.55% 8.14%
Return on Equity Simple (ROE_SIMPLE)		 -83.45% -85.50% -42.22% -56.84% 27.79% -18.31% -34.45% -44.29% -77.13% -328.77% 0.00%
Net Operating Profit after Tax (NOPAT)		 -67 -57 -26 -39 61 -65 -104 -125 -144 -421 57
NOPAT Margin		 -17,586.85% -36,138.97% -82.45% -242.56% 36.16% -74.11% -75.44% -51.37% -59.61% -11,848.94% 6.93%
Net Nonoperating Expense Percent (NNEP)		 -18.06% -27.13% -11.64% -22.28% 3.68% -5.12% -6.85% -9.41% -16.84% -79.42% -5.75%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - - - 7.58%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 6,409.74% 14,902.07% 55.72% 118.38% 15.73% 59.41% 58.56% 51.16% 38.44% 2,781.22% 14.94%
R&D to Revenue		 15,028.83% 39,232.39% 162.08% 328.13% 48.02% 146.46% 149.21% 122.23% 146.71% 14,245.85% 73.20%
Operating Expenses to Revenue		 25,224.08% 51,727.09% 217.79% 446.52% 63.75% 205.87% 207.77% 173.39% 185.16% 17,027.06% 88.14%
Earnings before Interest and Taxes (EBIT)		 -93 -82 -35 -55 61 -94 -147 -178 -203 -603 104
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -89 -78 -30 -50 67 -87 -138 -164 -193 -587 122
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.11 4.67 3.98 17.61 10.98 9.54 15.92 8.78 10.61 12.99 10.23
Price to Tangible Book Value (P/TBV)		 4.02 6.08 5.31 21.91 11.80 9.87 16.47 9.05 11.03 13.61 10.38
Price to Revenue (P/Rev)		 897.19 2,820.10 10.31 104.53 15.91 50.06 47.07 14.38 11.96 678.12 5.75
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 39.51 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 2.53% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 21.00 29.33 14.62 76.67 0.00 449.11 0.00 0.00 0.00 156.29 0.00
Enterprise Value to Revenue (EV/Rev)		 639.20 2,294.66 8.28 99.90 14.11 44.91 42.63 12.48 10.79 629.92 4.99
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 35.71 0.00 0.00 0.00 0.00 0.00 34.02
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 38.93 0.00 0.00 0.00 0.00 0.00 39.97
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 39.03 0.00 0.00 0.00 0.00 0.00 72.06
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 13.77 0.00 34.41 0.00 0.00 0.00 23.07
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 16.91 0.00 54.07 0.00 0.00 0.00 34.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.01 0.03 0.03 0.02 0.00 0.00 0.00 0.00 0.36 2.64 0.51
Long-Term Debt to Equity		 0.00 0.03 0.03 0.02 0.00 0.00 0.00 0.00 0.36 2.64 0.43
Financial Leverage		 -1.00 -0.88 -0.83 -0.78 -1.11 -1.07 -1.22 -1.32 -1.11 -0.99 -1.37
Leverage Ratio		 1.14 1.27 1.32 1.22 1.36 1.24 1.42 1.70 2.07 3.98 3.64
Compound Leverage Factor		 1.13 1.27 1.30 1.20 1.51 1.11 1.36 1.65 2.10 4.05 1.81
Debt to Total Capital		 0.69% 2.79% 3.04% 2.38% 0.00% 0.00% 0.00% 0.00% 26.70% 72.52% 33.61%
Short-Term Debt to Total Capital		 0.20% 0.20% 0.25% 0.23% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 5.28%
Long-Term Debt to Total Capital		 0.49% 2.59% 2.79% 2.15% 0.00% 0.00% 0.00% 0.00% 26.70% 72.52% 28.34%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -0.50% -0.57% -0.67% -0.57% -0.23% 0.00% 0.00% 4.74% 4.04% 0.81% 4.93%
Common Equity to Total Capital		 99.82% 97.78% 97.63% 98.19% 100.23% 100.00% 100.00% 95.26% 69.26% 26.67% 61.46%
Debt to EBITDA		 -0.01 -0.03 -0.08 -0.05 0.00 0.00 0.00 0.00 -0.54 -0.86 2.09
Net Debt to EBITDA		 1.10 1.05 2.09 1.47 0.00 0.00 0.00 0.00 1.55 0.30 -5.46
Long-Term Debt to EBITDA		 -0.01 -0.03 -0.08 -0.04 0.00 0.00 0.00 0.00 -0.54 -0.86 1.77
Debt to NOPAT		 -0.01 -0.05 -0.10 -0.06 0.00 0.00 0.00 0.00 -0.73 -1.20 4.44
Net Debt to NOPAT		 1.46 1.44 2.44 1.90 0.00 0.00 0.00 0.00 2.08 0.42 -11.56
Long-Term Debt to NOPAT		 -0.01 -0.04 -0.09 -0.05 0.00 0.00 0.00 0.00 -0.73 -1.20 3.74
Altman Z-Score		 4.21 2.23 2.33 54.96 15.19 42.39 11.60 5.98 1.66 -1.59 3.10
Noncontrolling Interest Sharing Ratio		 -0.40% -0.54% -0.63% -0.63% -0.33% -0.08% 0.00% 2.40% 5.05% 4.48% 6.19%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.47 3.53 3.63 6.37 2.73 7.92 2.62 2.92 3.95 6.74 4.86
Quick Ratio		 6.21 3.33 3.51 6.22 2.67 7.78 2.58 2.72 3.83 6.60 4.74
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -89 -58 -31 -42 141 -133 109 -266 -196 -447 122
Operating Cash Flow to CapEx		 -548.93% -1,669.00% -302.33% -3,322.66% 1,441.84% -801.55% 726.91% -257.94% -87.07% -327.17% 792.16%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -10.67 -13.81 1.36
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -8.40 -14.31 2.01
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -18.04 -18.68 1.76
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.27 0.15 0.73 0.20 0.22 0.35 0.33 0.00 0.66
Accounts Receivable Turnover		 0.00 0.00 439.89 81.70 341.44 116.75 24.91 41.70 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.09 0.02 2.03 1.10 9.09 3.25 3.48 3.06 1.20 0.01 2.16
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.83 4.47 1.07 3.13 14.65 8.75 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.83 4.47 1.07 3.13 14.65 8.75 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 12 12 18 21 -59 8.80 -205 -64 -12 14 -161
Invested Capital Turnover		 0.55 0.01 2.08 0.83 -8.93 -3.52 -1.41 -1.81 -6.35 2.89 -6.44
Increase / (Decrease) in Invested Capital		 22 0.76 5.41 3.24 -80 68 -213 141 52 26 -64
Enterprise Value (EV)		 244 363 260 1,613 2,382 3,952 5,896 3,036 2,597 2,237 4,141
Market Capitalization		 343 447 324 1,687 2,686 4,405 6,509 3,498 2,880 2,408 4,769
Book Value per Share		 $1.85 $1.57 $1.09 $1.09 $2.57 $4.51 $3.92 $3.77 $2.53 $1.49 $3.37
Tangible Book Value per Share		 $1.43 $1.21 $0.82 $0.88 $2.39 $4.36 $3.79 $3.65 $2.44 $1.42 $3.32
Total Capital		 110 98 83 98 244 462 409 418 392 695 758
Total Debt		 0.76 2.73 2.53 2.33 0.00 0.00 0.00 0.00 105 504 255
Total Long-Term Debt		 0.54 2.53 2.33 2.10 0.00 0.00 0.00 0.00 105 504 215
Net Debt		 -98 -83 -63 -74 -303 -453 -613 -482 -299 -177 -664
Capital Expenditures (CapEx)		 12 3.86 7.92 1.42 12 12 24 53 177 141 23
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -12 -20 -16 -9.91 -91 -34 -130 -110 -93 -89 -124
Debt-free Net Working Capital (DFNWC)		 87 65 49 67 168 282 238 266 311 592 795
Net Working Capital (NWC)		 87 65 49 66 168 282 238 266 311 592 755
Net Nonoperating Expense (NNE)		 25 25 8.48 15 -6.94 19 37 52 66 189 27
Net Nonoperating Obligations (NNO)		 -98 -83 -63 -74 -303 -453 -613 -482 -299 -177 -664
Total Depreciation and Amortization (D&A)		 3.45 3.49 4.65 5.08 5.51 6.47 8.53 13 10 15 18
Debt-free, Cash-free Net Working Capital to Revenue		 -3,027.78% -12,829.54% -51.57% -61.37% -53.63% -38.42% -93.81% -45.20% -38.47% -2,496.71% -14.98%
Debt-free Net Working Capital to Revenue		 22,824.12% 41,086.23% 157.32% 412.75% 99.63% 320.13% 172.15% 109.55% 129.19% 16,679.89% 95.87%
Net Working Capital to Revenue		 22,767.17% 40,963.51% 156.66% 411.36% 99.63% 320.13% 172.15% 109.55% 129.19% 16,679.89% 91.04%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.60) ($1.34) ($0.47) ($0.65) $0.72 ($0.84) ($1.36) ($1.67) ($1.92) ($5.00) ($0.01)
Adjusted Weighted Average Basic Shares Outstanding		 59.55M 74.17M 74.83M 92.22M 93.86M 100.72M 103.75M 105.43M 106.75M 119.78M 133.76M
Adjusted Diluted Earnings per Share		 ($1.60) ($1.34) ($0.47) ($0.65) $0.69 ($0.84) ($1.36) ($1.67) ($1.92) ($5.00) ($0.01)
Adjusted Weighted Average Diluted Shares Outstanding		 59.55M 74.17M 74.83M 92.22M 98.61M 100.72M 103.75M 105.43M 106.75M 119.78M 133.76M
Adjusted Basic & Diluted Earnings per Share		 ($1.60) ($1.34) ($0.47) ($0.65) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 57.36M 61.05M 73.90M 83.64M 95.71M 102.76M 104.53M 106.01M 107.43M 124.43M 135.81M
Normalized Net Operating Profit after Tax (NOPAT)		 -66 -60 -26 -39 61 -65 -104 -125 -144 -421 57
Normalized NOPAT Margin		 -17,240.24% -37,824.12% -82.45% -242.56% 36.16% -74.11% -75.44% -51.37% -59.61% -11,848.94% 6.93%
Pre Tax Income Margin		 -24,067.67% -51,613.12% -109.46% -337.30% 40.37% -96.09% -101.85% -71.01% -85.78% -17,247.54% 6.21%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -11.10 -18.63 1.16
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -7.83 -13.01 0.64
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -20.75 -23.01 0.91
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -17.47 -17.38 0.39
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Arrowhead Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Arrowhead Pharmaceuticals' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 140,032,190.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 140,032,190.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -0.95
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -49.02% -94.32% -100.00% -100.00% 0.00% -29.60% 0.00% 0.00% 0.00% 10,461.32% -86.41%
EBITDA Growth		 -30.63% -246.94% -339.16% -63.50% -63.67% -21.74% 426.22% 1.44% 131.44% 129.69% -130.47%
EBIT Growth		 -28.51% -227.01% -361.56% -71.28% -53.63% -18.33% 402.88% 5.51% 129.50% 125.51% -132.46%
NOPAT Growth		 -29.23% -224.07% -283.40% -71.51% -49.73% -18.21% 529.50% 6.01% 117.34% 136.08% -126.06%
Net Income Growth		 -29.17% -223.78% -366.37% -67.08% -56.14% -29.43% 389.67% -2.69% 109.30% 116.12% -137.40%
EPS Growth		 -27.50% -217.95% -326.67% -43.75% -33.33% -12.10% 369.61% 8.70% 91.91% 115.83% -133.82%
Operating Cash Flow Growth		 62.28% -56.05% -191.68% -455.51% -429.26% -24.13% 598.02% -34.05% 114.93% 109.22% -81.65%
Free Cash Flow Firm Growth		 35.83% -386.57% -113.73% -15.34% -9.23% 78.35% 363.10% 60.64% 392.98% 268.00% -85.34%
Invested Capital Growth		 81.45% 148.39% 685.99% 144.04% 220.72% -68.15% -136.93% -340.84% -66.54% -322.77% -541.36%
Revenue Q/Q Growth		 1.72% -77.94% -100.00% 0.00% 0.00% 0.00% 21,608.36% -94.88% 823.66% 2.95% -72.07%
EBITDA Q/Q Growth		 -4.67% -26.69% 9.76% -36.63% -4.78% 5.77% 341.82% -141.28% 133.43% -14.18% -355.39%
EBIT Q/Q Growth		 -5.09% -26.49% 7.44% -39.19% 5.74% 2.57% 336.94% -143.42% 129.42% -15.74% -401.49%
NOPAT Q/Q Growth		 -5.48% -26.05% 7.58% -39.58% 7.91% 0.49% 435.78% -130.54% 116.99% 107.10% -342.55%
Net Income Q/Q Growth		 -6.62% -21.94% 6.19% -36.99% 0.36% -1.08% 309.95% -148.56% 109.02% 75.19% -587.12%
EPS Q/Q Growth		 -6.25% -21.57% 17.74% -35.29% 1.45% -2.21% 297.84% -145.82% 91.27% 300.00% -522.73%
Operating Cash Flow Q/Q Growth		 -24.78% -354.52% 21.61% -24.94% -18.89% -6.60% 414.52% -133.63% 113.24% -34.21% 526.38%
Free Cash Flow Firm Q/Q Growth		 13.32% -139.19% 38.25% 9.91% 17.92% 52.58% 850.30% -113.48% 225.43% 32.43% -34.52%
Invested Capital Q/Q Growth		 63.59% 678.54% 25.27% -83.31% -0.22% 52.67% -245.21% -8.88% -366.27% 69.78% -318.05%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -650.69% -3,736.86% 0.00% 0.00% 0.00% -6,461.60% 71.98% -580.76% 21.02% 17.52% -160.22%
Operating Margin		 -672.98% -3,845.25% 0.00% 0.00% 0.00% -6,456.48% 70.24% -596.21% 17.20% 15.46% -191.57%
EBIT Margin		 -668.53% -3,833.40% 0.00% 0.00% 0.00% -6,442.84% 70.32% -596.85% 19.01% 15.56% -167.99%
Profit (Net Income) Margin		 -689.66% -3,812.33% 0.00% 0.00% 0.00% -7,008.72% 67.78% -643.40% 6.29% 10.70% -186.57%
Tax Burden Percent		 101.86% 97.61% 100.00% 100.00% 100.32% 100.06% 99.53% 99.76% 44.63% 99.90% 100.01%
Interest Burden Percent		 101.28% 101.88% 100.79% 99.20% 104.52% 108.72% 96.85% 108.06% 74.08% 68.81% 111.06%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.47% 0.00% 55.37% 0.10% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -249.86% 1,406.56% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% -160.54% 1,408.61% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 97.35% -1,343.89% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -59.33% -106.24% 0.00% -151.84% 0.00% -152.50% 62.67% -37.11% 8.67% 75.50% -42.37%
Cash Return on Invested Capital (CROIC)		 0.00% -612.23% -503.04% -2,997.65% -3,122.72% -865.57% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -220.84% -918.03% 0.00% 0.00% 0.00% -19.64% 30.32% -302.05% 12.49% 12.97% -54.40%
Return on Assets (ROA)		 -227.82% -912.99% 0.00% 0.00% 0.00% -21.37% 29.23% -325.61% 4.13% 8.92% -60.41%
Return on Common Equity (ROCE)		 -56.33% -100.16% 0.00% -146.46% 0.00% -141.36% 62.00% -36.86% 8.14% 75.77% -42.84%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -188.79% -98.70% -165.59% 0.00% -1,235.12% -22.64% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -76 -96 -88 -123 -114 -113 379 -116 20 41 -99
NOPAT Margin		 -471.09% -2,691.68% 0.00% 0.00% 0.00% -4,519.54% 69.91% -417.35% 7.68% 15.44% -134.10%
Net Nonoperating Expense Percent (NNEP)		 -9.01% -12.37% -8.70% -13.71% -25.14% -89.32% -2.05% -14.28% -0.75% -3.88% -5.10%
Return On Investment Capital (ROIC_SIMPLE)		 - -33.09% - - - -19.66% 35.60% -13.38% 2.60% 4.70% -6.26%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 152.65% 664.74% 0.00% 0.00% 0.00% 1,076.40% 5.23% 111.46% 14.69% 17.43% 56.61%
R&D to Revenue		 620.33% 3,280.51% 0.00% 0.00% 0.00% 5,480.08% 24.53% 584.75% 68.11% 67.11% 234.96%
Operating Expenses to Revenue		 772.98% 3,945.25% 0.00% 0.00% 0.00% 6,556.48% 29.76% 696.21% 82.80% 84.54% 291.57%
Earnings before Interest and Taxes (EBIT)		 -108 -136 -126 -175 -165 -161 382 -166 49 41 -124
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -105 -133 -120 -164 -171 -162 391 -161 54 46 -118
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 10.61 20.45 7.32 9.77 12.99 44.48 2.35 4.18 10.23 15.86 14.30
Price to Tangible Book Value (P/TBV)		 11.03 21.78 7.47 10.04 13.61 52.63 2.38 4.24 10.38 16.04 14.44
Price to Revenue (P/Rev)		 11.96 18.05 99.89 164.29 678.12 935.75 2.95 3.81 5.75 8.26 14.12
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 44.58 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.24% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 46.48 36.61 203.01 156.29 105.66 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 10.79 17.54 88.68 148.20 629.92 923.45 1.64 2.84 4.99 7.70 12.80
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 34.02 25.39 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 39.97 27.47 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 72.06 30.50 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 14.58 74.39 23.07 24.75 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 25.72 0.00 34.00 24.28 484.47
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.36 0.66 0.23 0.33 2.64 9.25 0.56 0.67 0.51 0.54 1.64
Long-Term Debt to Equity		 0.36 0.66 0.23 0.33 2.64 9.22 0.46 0.59 0.43 0.47 1.57
Financial Leverage		 -1.11 -1.13 -0.93 -1.03 -0.99 -0.61 -0.95 -1.02 -1.37 -1.04 -1.18
Leverage Ratio		 2.07 2.66 1.92 2.33 3.98 7.14 2.14 2.64 3.64 4.23 2.99
Compound Leverage Factor		 2.09 2.71 1.94 2.31 4.16 7.76 2.08 2.85 2.69 2.91 3.33
Debt to Total Capital		 26.70% 39.86% 18.66% 24.84% 72.52% 90.24% 35.79% 39.96% 33.61% 35.17% 62.11%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.28% 6.10% 4.62% 5.28% 4.61% 2.53%
Long-Term Debt to Total Capital		 26.70% 39.86% 18.66% 24.84% 72.52% 89.96% 29.70% 35.34% 28.34% 30.56% 59.58%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 4.04% 4.61% 1.91% 1.87% 0.81% 0.61% 0.08% -0.29% 4.93% -0.66% -0.95%
Common Equity to Total Capital		 69.26% 55.53% 79.44% 73.29% 26.67% 9.15% 64.12% 60.33% 61.46% 65.49% 38.84%
Debt to EBITDA		 -0.54 -0.40 -0.25 -0.22 -0.86 -0.84 -3.60 -3.34 2.09 0.92 -5.48
Net Debt to EBITDA		 1.55 0.37 0.90 0.62 0.30 0.06 6.76 5.35 -5.46 -1.85 4.48
Long-Term Debt to EBITDA		 -0.54 -0.40 -0.25 -0.22 -0.86 -0.84 -2.99 -2.95 1.77 0.80 -5.25
Debt to NOPAT		 -0.73 -0.55 -0.34 -0.29 -1.20 -1.18 -4.60 -4.58 4.44 1.11 -6.32
Net Debt to NOPAT		 2.08 0.50 1.23 0.85 0.42 0.08 8.63 7.34 -11.56 -2.22 5.17
Long-Term Debt to NOPAT		 -0.73 -0.55 -0.34 -0.29 -1.20 -1.18 -3.81 -4.05 3.74 0.96 -6.06
Altman Z-Score		 2.07 1.66 2.94 1.10 -0.33 -0.98 1.66 0.57 2.97 5.18 3.00
Noncontrolling Interest Sharing Ratio		 5.05% 5.73% 0.00% 3.55% 0.00% 7.31% 1.06% 0.69% 6.19% -0.36% -1.10%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.95 3.73 8.31 4.65 6.74 6.09 5.15 4.87 4.86 3.38 6.23
Quick Ratio		 3.83 3.46 8.03 4.52 6.60 5.92 4.99 4.68 4.74 3.27 6.10
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -128 -306 -189 -170 -140 -66 497 -67 84 111 73
Operating Cash Flow to CapEx		 -40.57% -171.64% -271.10% -798.80% -564.93% -1,946.14% 8,685.16% -6,544.84% 273.61% 627.61% 3,292.09%
Free Cash Flow to Firm to Interest Expense		 -24.31 -57.00 -26.08 -33.41 -9.54 -3.06 22.97 -2.75 3.87 4.95 3.06
Operating Cash Flow to Interest Expense		 -4.93 -21.96 -12.75 -22.66 -9.37 -6.76 21.26 -6.35 0.94 0.60 3.54
Operating Cash Flow Less CapEx to Interest Expense		 -17.07 -34.75 -17.46 -25.49 -11.03 -7.10 21.02 -6.44 0.60 0.50 3.43
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.33 0.24 0.04 0.02 0.00 0.00 0.43 0.51 0.66 0.83 0.32
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 9.86 68.92
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.20 0.76 0.13 0.06 0.01 0.01 1.47 1.51 2.16 2.85 1.64
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 37.03 5.30
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 37.03 5.30
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -12 69 86 14 14 22 -32 -35 -161 -49 -203
Invested Capital Turnover		 -6.35 -4.97 1.00 -2.16 2.89 0.06 20.12 -56.73 -6.44 -81.34 -5.29
Increase / (Decrease) in Invested Capital		 52 210 101 47 26 -47 -118 -49 -64 -71 -172
Enterprise Value (EV)		 2,597 3,188 3,146 2,912 2,237 2,309 891 1,625 4,141 8,399 7,963
Market Capitalization		 2,880 3,280 3,543 3,228 2,408 2,339 1,606 2,182 4,769 9,016 8,780
Book Value per Share		 $2.53 $1.49 $3.90 $2.66 $1.49 $0.42 $5.42 $3.78 $3.37 $4.19 $4.38
Tangible Book Value per Share		 $2.44 $1.40 $3.83 $2.59 $1.42 $0.36 $5.36 $3.73 $3.32 $4.14 $4.34
Total Capital		 392 289 609 451 695 575 1,066 866 758 868 1,581
Total Debt		 105 115 114 112 504 519 381 346 255 305 982
Total Long-Term Debt		 105 115 114 112 504 517 316 306 215 265 942
Net Debt		 -299 -105 -409 -325 -177 -34 -716 -554 -664 -611 -802
Capital Expenditures (CapEx)		 64 69 34 14 24 7.52 5.30 2.36 7.49 2.15 2.57
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -93 -46 -47 -83 -89 -75 -118 -108 -124 -50 -200
Debt-free Net Working Capital (DFNWC)		 311 174 476 353 592 478 980 792 795 867 1,585
Net Working Capital (NWC)		 311 174 476 353 592 477 915 752 755 827 1,545
Net Nonoperating Expense (NNE)		 35 40 39 51 60 62 12 63 3.56 13 39
Net Nonoperating Obligations (NNO)		 -299 -105 -409 -325 -177 -34 -716 -554 -664 -611 -802
Total Depreciation and Amortization (D&A)		 2.87 3.43 6.26 12 -6.11 -0.47 9.00 4.47 5.14 5.18 5.73
Debt-free, Cash-free Net Working Capital to Revenue		 -38.47% -25.37% -131.48% -424.08% -2,496.71% -2,981.28% -21.59% -18.85% -14.98% -4.55% -32.08%
Debt-free Net Working Capital to Revenue		 129.19% 95.84% 1,343.20% 1,798.39% 16,679.89% 19,136.12% 179.69% 138.29% 95.87% 79.47% 254.74%
Net Working Capital to Revenue		 129.19% 95.84% 1,343.20% 1,798.39% 16,679.89% 19,071.12% 167.77% 131.31% 91.04% 75.80% 248.31%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.03) ($1.24) ($1.02) ($1.38) ($1.36) ($1.39) $2.78 ($1.26) ($0.14) $0.22 ($0.93)
Adjusted Weighted Average Basic Shares Outstanding		 106.75M 107.42M 123.29M 124.20M 119.78M 124.85M 133.36M 139.04M 133.76M 137.04M 142.42M
Adjusted Diluted Earnings per Share		 ($1.02) ($1.24) ($1.02) ($1.38) ($1.36) ($1.39) $2.75 ($1.26) ($0.11) $0.22 ($0.93)
Adjusted Weighted Average Diluted Shares Outstanding		 106.75M 107.42M 123.29M 124.20M 119.78M 124.85M 134.48M 139.04M 133.76M 140.71M 142.42M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 107.43M 123.90M 124.20M 124.32M 124.43M 126.10M 138.10M 138.26M 135.81M 140.03M 140.86M
Normalized Net Operating Profit after Tax (NOPAT)		 -76 -96 -88 -123 -114 -113 379 -116 31 41 -99
Normalized NOPAT Margin		 -471.09% -2,691.68% 0.00% 0.00% 0.00% -4,519.54% 69.91% -417.35% 12.04% 15.44% -134.10%
Pre Tax Income Margin		 -677.08% -3,905.63% 0.00% 0.00% 0.00% -7,004.60% 68.11% -644.97% 14.08% 10.71% -186.56%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -20.45 -25.36 -17.39 -34.43 -11.29 -7.44 17.64 -6.80 2.25 1.83 -5.19
NOPAT to Interest Expense		 -14.41 -17.81 -12.19 -24.20 -7.75 -5.22 17.53 -4.75 0.91 1.81 -4.15
EBIT Less CapEx to Interest Expense		 -32.60 -38.16 -22.10 -37.27 -12.95 -7.79 17.39 -6.89 1.90 1.73 -5.30
NOPAT Less CapEx to Interest Expense		 -26.56 -30.60 -16.90 -27.04 -9.41 -5.57 17.29 -4.85 0.56 1.72 -4.25
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Arrowhead Pharmaceuticals (ARWR) has shown a highly variable quarterly pattern over the last four years. The company continues to invest heavily in R&D, leading to large occasional losses, but it also posted a notable net income point in 2026 Q1 and maintained a sizable liquidity cushion through a mix of cash, short-term investments, and periodic financing activity. Here are the key takeaways for retail investors from the four-year window ending in 2026 Q1.

  • Q1 2026 net income attributable to common shareholders: $30,811,000. This marks a positive quarterly result at the shareholder level.
  • Q1 2026 earnings per share: Basic $0.22, Diluted $0.22 per share, indicating a positive earnings signal for that quarter.
  • Strong liquidity position at 2026 Q1: Cash & Equivalents about $201.6M and Short-Term Investments around $714.9M, giving roughly $0.92B in liquid assets combined.
  • Solid asset base and equity position (2026 Q1): Total Assets about $1.604B; Total Equity around $568.4M, suggesting a positive equity base despite ongoing complexity in the business model.
  • 2025 equity financing: Issuance of Common Equity in 2025 Q2 raised approximately $241.4M, providing financing flexibility for investing activities or balance-sheet needs.
  • Revenue volatility across quarters: Quarter-to-quarter revenue swings are pronounced, e.g., a spike to about $542.7M in 2025 Q2 followed by much lower levels in neighboring quarters, highlighting a highly variable top line.
  • Research & Development intensity remains high: RD expense is consistently in the range of roughly $160M–$180M per quarter (e.g., 2026 Q1 RD expense ≈ $177.2M; 2025 Q4 ≈ $174.7M), reflecting biotech R&D priorities.
  • Cash flow from operating activities often negative: Multiple quarters show negative net cash from continuing operating activities (e.g., 2025 Q3 around -$154.7M; 2025 Q4 around -$137.2M; 2024 periods also negative), indicating ongoing cash burn despite financing and investing activity.
  • Net income frequently negative across many quarters: Notable examples include 2025 Q3 net income -$178.7M and 2024 Q4 net income -$173.3M, underscoring the challenge of achieving sustained profitability.
  • Cash balance changes can be material to cash runways: 2026 Q1 Net Change in Cash & Equivalents around -$25.0M, with additional quarterly swings in other periods (e.g., 2025 Q3 about -$56.0M), implying ongoing variability in cash trajectory.
05/18/26 06:22 PM ETAI Generated. May Contain Errors.

Arrowhead Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Arrowhead Pharmaceuticals' fiscal year ends in September. Their fiscal year 2025 ended on September 30, 2025.

Arrowhead Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of $30.11 million in 2025, falling from -$91.94 million in 2015. The previous period was -$609.69 million in 2024. See where experts think Arrowhead Pharmaceuticals is headed by visiting Arrowhead Pharmaceuticals' forecast page.

Arrowhead Pharmaceuticals' total operating income in 2025 was $98.35 million, based on the following breakdown:
  • Total Gross Profit: $829.45 million
  • Total Operating Expenses: $731.10 million

Over the last 10 years, Arrowhead Pharmaceuticals' total revenue changed from $382 thousand in 2015 to $829.45 million in 2025, a change of 217,033.0%.

Arrowhead Pharmaceuticals' total liabilities were at $881.88 million at the end of 2025, a 7.0% decrease from 2024, and a 3,794.1% increase since 2015.

In the past 10 years, Arrowhead Pharmaceuticals' cash and equivalents has ranged from $24.84 million in 2017 to $226.55 million in 2025, and is currently $226.55 million as of their latest financial filing in 2025.

Over the last 10 years, Arrowhead Pharmaceuticals' book value per share changed from 1.85 in 2015 to 3.37 in 2025, a change of 82.0%.


Related Companies

Financial statements for NASDAQ:ARWR last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Peptide Company Lands Exclusive MMA Wellness Partnership
The Precision Peptide Company (OTCQB: PNGAF) just signed an exclusive partnership with a NYSE-listed MMA media...
The Tomorrow Investor | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
Musk’s warning just revealed a $1T opportunity
Elon Musk recently warned that AI could force governments to introduce universal income. Mode Mobile isn't wai...
Mode Mobile | Sponsoredtc pixel
Memorial Day Sale! 85% Off Disruptors and Dominators!
Nvidia's Jensen Huang has laid out a plan for the world's first trillion-dollar robot - and one virtually unkn...
Weiss Ratings | Sponsoredtc pixel
Your $29.97 book is free today
Bill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...
Profits Run | Sponsoredtc pixel